Skip to content
Clinical Trials – home

Hospital Vall d’Hebron

Verified siteinfo

Spain Edificio Materno-Infantil, Passeig De La Vall D'hebron 119-129, 08035 Barcelona, Spain

  • 818 trials recruiting
  • Non-small cell lung cancer · Neoplasm · Neoplasm malignant
  • Adults and children

About Specializations

Hospital Vall d’Hebron in Barcelona, Spain specialises in clinical trials of conditions such as Non-small cell lung cancer, Neoplasm, Neoplasm malignant, Breast cancer, and other specialisations. This site conducts important research.

Main research areas of the site

Cardiovascular Diseases at Hospital Vall d’Hebron

Research here focuses on pulmonary arterial hypertension, a serious condition affecting the blood vessels in the lungs. The trials are designed to explore whether targeted supportive treatment can improve symptoms, functional capacity, and risk status while helping prevent clinical worsening.

  • Studying pulmonary arterial hypertension in patients with idiopathic, hereditary, drug- and toxin-induced, and connective tissue disease-associated forms
  • Evaluating vitamin D supplementation as a potential way to improve clinical outcomes and reduce worsening of disease

This work reflects a strong interest in better managing cardiopulmonary complications through more effective supportive care and outcome monitoring.

Immune System Diseases

The Lupus Unit at Vall d’Hebron Institut de Recerca is conducting research in systemic lupus erythematosus, especially severe and treatment-resistant cases. These studies aim to assess new therapeutic options for improving disease control and safety in people with difficult-to-manage autoimmune disease.

  • Investigating severe, refractory systemic lupus erythematosus in patients who need better treatment options
  • Testing a new cell-based therapy to evaluate early signs of benefit and tolerability

The research highlights ongoing efforts to advance care for complex autoimmune diseases by finding approaches that may offer meaningful improvement where standard treatments are not enough.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease? Our clinical trial advisor will do it for you.

Site location
Edificio Materno-Infantil, Passeig De La Vall D'hebron 119-12908035 BarcelonaSpain
Recruiting now
818 trials
Conditions studied
688
Partner status
Verified site

More sites in BarcelonaSpain

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

2 110 clinical trials

Cardiac failure

Recruiting

Study of maridebart cafraglutide for patients with heart failure with preserved or mildly reduced ejection fraction and obesity

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Maridebart Cafraglutide
  • Sponsor:Amgen Inc.

Phase III Randomized Study of Balcinrenone and Dapagliflozin Versus Dapagliflozin on Renal and Cardiovascular Outcomes in Patients with Chronic Kidney Disease Stage 3b‑4

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Balcinrenone
  • Sponsor:AstraZeneca AB

Phase 3 Randomized, Double‑Blind Study of Telitacicept versus Placebo for Efficacy and Safety in Adults with Active Primary Sjögren’s Disease

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Telitacicept
  • Sponsor:Vor Biopharma Inc.

Effect of lenbelintide (AZD6234) on body weight in adults with type 2 diabetes and obesity or overweight

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:AZD6234
  • Sponsor:AstraZeneca AB

Efficacy and Safety of Lebrikizumab in Adults and Adolescents with Moderate-to-Severe Face and Neck Atopic Dermatitis

Registered drug
Countries:SpainSpain
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Lebrikizumab
  • Sponsor:Almirall S.A.

Phase 3 Study of atebimetinib with gemcitabine and paclitaxel versus gemcitabine and paclitaxel in patients with metastatic pancreatic cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Atebimetinib
  • Sponsor:Immuneering Corp.

Obesity+2

Recruiting

Effect of zenagamtide on major adverse cardiovascular events in overweight or obese adults with established atherosclerotic cardiovascular disease

Investigational
Countries:SpainSpain
  • Participants:18–64 years
  • Substances:Zenagamtide
  • Sponsor:Novo Nordisk A/S

A Phase 3 Randomized Study of Rozanolixizumab for Safety and Efficacy in Adults with Ocular Myasthenia Gravis

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Rozanolixizumab
  • Sponsor:UCB Biopharma

Randomized Phase III trial of elecoglipron plus dapagliflozin on kidney outcomes and mortality in adults with chronic kidney disease

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:AZD5004
  • Sponsor:AstraZeneca AB

Narcolepsy

Recruiting

Efficacy and Safety of ALKS 2680 and Alixorexton in Adults with Narcolepsy Type 1

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:ALKS 2680
  • Sponsor:Alkermes Inc.
Countries:SpainSpain
  • Participants:18–64 years
  • Substances:Orelabrutinib
  • Sponsor:Zenas Biopharma (USA) LLC

Phase 2 Study of Nemolizumab for Skin Thickening in Adults with Systemic Sclerosis

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Nemolizumab
  • Sponsor:Galderma S.A.
Is this your site?

Join our network of research sites

Move up to Verified & featured: your own description, photos and phone number on this page, and top placement on every trial you run.

See the offer for sites
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease? Our clinical trial advisor will do it for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.